Close Menu

NEW YORK – Despite a shortfall in second-quarter revenues due to delayed population genomics projects and weakness in the direct-to-consumer genetic testing market, Illumina believes that growth in these areas will eventually return, according to CEO and President Francis deSouza.

During a conference call to discuss Illumina's second quarter results this week, he provided additional details on why Q2 revenues stayed below expectations and highlighted other areas of potential growth, including oncology, clinical genetics, reproductive health, and clinical research.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.